Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott and Barr resolve Femcon Fe patent litigation
Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately seven years
Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately seven years
Baxter has acquired all rights to AV513, a compound poised for clinical research that has been shown to improve blood coagulation in preclinical models for hemophilia. Avigen has
Flamel Technologies is engaged in 17 partnered projects and is working with seven of the top-twenty pharmaceutical companies in the world, including a continuing research collaboration with Pfizer.
Since 1998, Mr Lerman has served as a litigation partner at Winston & Strawn in Chicago, where he concentrated his practice in white-collar defense, product liability and securities
Vasovist is the first contrast agent approved for marketing in the US for use with MRA, a non-invasive modality for imaging blood vessels, the company said. Vasovist had
Abstral is a rapid dissolving, sub-lingual tablet of fentanyl, indicated for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. Abstral is currently
This tranche was dominated by a new investment from Baxter International to go along with the September 2008 investments by new investors Genzyme Ventures and Mitsubishi UFJ Capital.
The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC osteoarthritis (OA) score from baseline to day 21
Aplenzin, which was approved by the FDA in April 2008, is indicated for the treatment of major depressive disorder. Biovail anticipates that Sanofi Aventis US will launch the
In Phase III studies Firmagon (degarelix) produced a significant reduction in levels of testosterone within three days in more than 96% of study patients. Testosterone plays a major